A recent report that the JAK inhibitor (ruxolitinib) almost completely inhibited CLL-cell proliferation induced by CD154 + IL-21 [39], suggests that the JAK-STAT pathway may dominate over AKT in transmitting proliferation signals under these circumstances. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.